NASDAQ: CRMD · Life Sciences · 8 alerts · CIK 1410098
Share price
$4.82Close, Nov 16
Market cap
$383M
Shares outstanding
79.54MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All CorMedix Inc. filings on SEC EDGAR ↗
CorMedix Inc. announced a definitive agreement to acquire substantially all of the assets of Heron Therapeutics, Inc., including both commercial and pipeline assets. The acquisition is intended to provide scale and diversification to CorMedix's institutional care growth strategy and remains subject to Heron stockholder approval and regulatory clearance.
CorMedix Inc. has entered into a definitive asset purchase agreement to acquire substantially all of the assets of Heron Therapeutics. The transaction will be funded in part through a new term loan facility with Pharmakon and the issuance of CorMedix common stock as consideration. The deal is expected to be accretive to earnings and free cash flow while providing operating cost synergies.
CorMedix Signs $145M M&A Deal with Heron Therapeutics, Inc.
CorMedix Inc. has entered into a definitive agreement to acquire substantially all assets of Heron Therapeutics for $145 million in cash and 14,583,333 shares of common stock. The deal adds four commercial-stage products (ZYNRELEF, APONVIE, CINVANTI, and SUSTOL) to CorMedix's institutional care portfolio and includes up to $55 million in potential earn-out payments. To fund the transaction, CorMedix secured a new $75 million senior secured term loan facility from Pharmakon Advisors.